Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT)

Status: open

Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma

Treatment for Hodgkin´s Lymphoma

Contact Us Or call (251) 445-9834

Description

The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant

Sponsors

This trial is sponsored by Bristol-Myers Squibb.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.